CIBC Asset Management Inc Boosts Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• CIBC Asset Management increased its Merck stake by 51.6% in the fourth quarter, ending with 720,718 shares worth about $75.9 million.
• Recent pipeline news is broadly positive, including the FDA granting Breakthrough Therapy Designation for calderasib with Keytruda and five-year melanoma data showing a 49% reduction in recurrence or death risk versus Keytruda alone.
• Merck also reported solid financial and shareholder-return updates, with quarterly earnings and revenue beating estimates and a new $0.85 quarterly dividend set to be paid in July.

CIBC Asset Management Inc boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 51.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 720,718 shares of the company's stock after purchasing an additional 245,419 shares during the period. CIBC Asset Management Inc's holdings in Merck & Co., Inc. were worth $75,863,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $3,997,933,000. DLD Asset Management LP raised its holdings in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company's stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the period. Jennison Associates LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $585,192,000. Invesco Ltd. raised its holdings in shares of Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company's stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company's stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares during the period. Hedge funds and other institutional investors own 76.07% of the company's stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck said the FDA granted Breakthrough Therapy Designation for calderasib in combination with Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant non-small cell lung cancer patients, which may speed development and improve the drug’s commercial outlook. Article Title
• Positive Sentiment: Moderna and Merck presented five-year data for their melanoma combination therapy, showing a 49% reduction in recurrence or death risk versus Keytruda alone, reinforcing confidence in Merck’s oncology pipeline and Keytruda’s franchise. Article Title
• Positive Sentiment: Reports highlighted possible new EU approval momentum for Keytruda, which would expand the drug’s reach outside the U.S. and support future revenue growth. Article Title
• Positive Sentiment: Merck announced a quarterly dividend, reinforcing its shareholder-return profile and signaling financial stability. Article Title
• Positive Sentiment: Merck is also strengthening its capital structure with a notes offering, which may improve liquidity and financial flexibility. Article Title
• Neutral Sentiment: Merck will participate in the Goldman Sachs Global Healthcare Conference, a routine investor event that could provide updates but does not by itself change fundamentals. Article Title
• Neutral Sentiment: Commentary from Jim Cramer noting that Merck’s cancer dominance has been challenged by J&J is more of a competitive observation than a direct catalyst, but it underscores pressure in oncology. Article Title
• Neutral Sentiment: Reuters reported Merck is discussing whether its COVID antiviral molnupiravir could be used in the Ebola response; this is potentially meaningful, but still exploratory. Article Title

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MRK. Cantor Fitzgerald raised their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a "neutral" rating in a research note on Wednesday, February 4th. Barclays began coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an "overweight" rating and a $140.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. Royal Bank Of Canada reiterated an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Wall Street Zen downgraded Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of "Moderate Buy" and a consensus price target of $128.18.

Merck & Co., Inc. Price Performance

MRK stock opened at $115.89 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52-week low of $75.43 and a 52-week high of $125.14. The stock's 50 day moving average is $116.42 and its two-hundred day moving average is $111.81. The company has a market capitalization of $286.23 billion, a PE ratio of 32.65, a P/E/G ratio of 2.59 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the business earned $2.22 EPS. Merck & Co., Inc.'s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.'s payout ratio is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.